Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs
复制标题
DOI：
10.1097/00042560-199709010-00009
复制
发表时间：
1997-09-01
期刊：
影响因子：
--
通讯作者：
Pinkerton, SD
中科院分区：
文献类型：
--
作者：
Holtgrave, DR;Pinkerton, SD
将有限的经济和其他资源分配给艾滋病毒预防和治疗，以实现最大效益？卫生政策规划者和决策者需要对艾滋病毒相关疾病的终生成本和治疗对艾滋病毒感染者生活质量的影响进行准确的、最新的估计。这些数据是称为成本-效用分析的经济评估方法的中心输入参数。文献中提供的估计已经过时，本文根据HIV诊断和治疗的最新进展，对美国与HIV疾病相关的预计终身保健成本和HN失去的质量调整生命年(QALY)数进行了更新估计。结果表明，艾滋病毒医疗保健的终生成本已经从大约55,000美元增加到超过155,000美元，而每个艾滋病毒感染病例失去的QALY数量从9.26个减少到7.10个，按5%的年率折扣。当这些数字以新建议的3%的利率贴现时，生命周期成本上升到19.5万美元以上，损失的QALY增加到11.23。这些通过避免艾滋病毒感染和QALY而节省的护理和治疗医疗成本的净影响使HN预防成为一种相对更具成本效益的战略，而不是其他与艾滋病毒健康相关的计划。
To allocate limited economic and other resources for HIV prevention and treatment for maximum benefit? health policy planners and decision makers require accurate, current estimates of the lifetime costs of HIV-related illness and the impact of therapy on the quality of life of HIV-infected persons. These data are central input parameters to the economic evaluation methodology known as cost-utility analysis. The estimates available in the literature are already outdated, and this paper presents updated estimates of the projected lifetime health care costs associated with HIV disease in the United States and the number of quality-adjusted life years (QALYs) lost to HN in light of recent advancements in HIV diagnostics and therapeutics. Results indicate that the lifetime cost of HIV medical care has grown from about $55,000 U.S. to more than $155,000 U.S., while the number of QALYs lost per case of HIV infection has decreased from 9.26 to 7.10, when discounted at a 5% annual rate. When these figures are discounted instead at the newly recommended 3% rate, lifetime costs rise to more than $195,000 U.S. and lost QALYs increase to 11.23. The net effect of these increases in the medical costs of care and treatment saved by averting an HIV infection and in QALYs makes HN prevention a relatively more cost-effective strategy than other, non-HIV health-related programs.